Shopping Cart 0
Cart Subtotal
USD 0

insulin like growth factor i (mechano growth factor or somatomedin c or igf1)-pipeline review, h2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Pipeline Review, H2 2017

Summary

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) pipeline Target constitutes close to 9 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Insulin Like Growth Factor I-Pipeline Review, H2 2017, outlays comprehensive information on the Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin. It plays a role in synapse maturation. It acts as a ligand for IGF1R. It binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiates a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. It binds to integrins ITGAV: ITGB3 and ITGA6:ITGB4. It also binds to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular and Musculoskeletal Disorders which include indications Metastatic Breast Cancer, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Breast Cancer, Cerebral Infarction (Brain Infarction), Hormone Sensitive Breast Cancer, Huntington Disease, Ischemic Cerebral Stroke, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Muscular Dystrophy, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Parkinson's Disease, Prostate Cancer and Solid Tumor.

Furthermore, this report also reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)

-The report reviews Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics and enlists all their major and minor projects

-The report assesses Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics

Reasons to buy

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)

-Identify the use of drugs for target identification and drug repurposing

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

-Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) development landscape

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Overview 6

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Companies Involved in Therapeutics Development 20

Boehringer Ingelheim GmbH 20

Genervon Biopharmaceuticals LLC 20

MedImmune LLC 21

Regulaxis SAS 21

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Drug Profiles 22

CIGB-845-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

dusigitumab-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

GM-6-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

M-610.27-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

M-630-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

M-7085-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Synthetic Peptides to Inhibit IGF1 for Oncology-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

xentuzumab-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Dormant Products 36

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Product Development Milestones 38

Featured News & Press Releases 38

Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published 38

Jan 10, 2017: Genervon Releases ALS, PD and AD Disease Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm 38

Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways 39

Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS 40

May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604 40

May 03, 2016: GM604 to Be Granted "Orphan Drug" Status in Europe 41

Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression 42

Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease 42

Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA 43

Jan 08, 2015: Genervon Announces ALS Compassionate Use Results 43

Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results 44

Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS 46

Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS 47

Mar 03, 2014: FDA Grants "Orphan Drug" Designation for Genervon's Breakthrough Multi-Target ALS Bio-Drug GM604 47

Jun 26, 2013: Genervon's GM604 Receives Fast Track Designation From FDA For Treatment Of Amyotrophic Lateral Sclerosis 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pipeline by Boehringer Ingelheim GmbH, H2 2017 20

Pipeline by Genervon Biopharmaceuticals LLC, H2 2017 20

Pipeline by MedImmune LLC, H2 2017 21

Pipeline by Regulaxis SAS, H2 2017 21

Dormant Products, H2 2017 36

Dormant Products, H2 2017 (Contd..1), H2 2017 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Boehringer Ingelheim GmbH

Genervon Biopharmaceuticals LLC

MedImmune LLC

Regulaxis SAS

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Pipeline Review, H2 2017

Summary

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) pipeline Target constitutes close to 9 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Insulin Like Growth Factor I-Pipeline Review, H2 2017, outlays comprehensive information on the Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin. It plays a role in synapse maturation. It acts as a ligand for IGF1R. It binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiates a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. It binds to integrins ITGAV: ITGB3 and ITGA6:ITGB4. It also binds to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular and Musculoskeletal Disorders which include indications Metastatic Breast Cancer, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Breast Cancer, Cerebral Infarction (Brain Infarction), Hormone Sensitive Breast Cancer, Huntington Disease, Ischemic Cerebral Stroke, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Muscular Dystrophy, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Parkinson's Disease, Prostate Cancer and Solid Tumor.

Furthermore, this report also reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)

-The report reviews Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics and enlists all their major and minor projects

-The report assesses Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics

Reasons to buy

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)

-Identify the use of drugs for target identification and drug repurposing

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

-Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) development landscape

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Overview 6

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Companies Involved in Therapeutics Development 20

Boehringer Ingelheim GmbH 20

Genervon Biopharmaceuticals LLC 20

MedImmune LLC 21

Regulaxis SAS 21

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Drug Profiles 22

CIGB-845-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

dusigitumab-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

GM-6-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

M-610.27-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

M-630-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

M-7085-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Synthetic Peptides to Inhibit IGF1 for Oncology-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

xentuzumab-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Dormant Products 36

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)-Product Development Milestones 38

Featured News & Press Releases 38

Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published 38

Jan 10, 2017: Genervon Releases ALS, PD and AD Disease Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm 38

Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways 39

Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS 40

May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604 40

May 03, 2016: GM604 to Be Granted "Orphan Drug" Status in Europe 41

Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression 42

Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease 42

Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA 43

Jan 08, 2015: Genervon Announces ALS Compassionate Use Results 43

Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results 44

Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS 46

Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS 47

Mar 03, 2014: FDA Grants "Orphan Drug" Designation for Genervon's Breakthrough Multi-Target ALS Bio-Drug GM604 47

Jun 26, 2013: Genervon's GM604 Receives Fast Track Designation From FDA For Treatment Of Amyotrophic Lateral Sclerosis 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pipeline by Boehringer Ingelheim GmbH, H2 2017 20

Pipeline by Genervon Biopharmaceuticals LLC, H2 2017 20

Pipeline by MedImmune LLC, H2 2017 21

Pipeline by Regulaxis SAS, H2 2017 21

Dormant Products, H2 2017 36

Dormant Products, H2 2017 (Contd..1), H2 2017 37

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Boehringer Ingelheim GmbH

Genervon Biopharmaceuticals LLC

MedImmune LLC

Regulaxis SAS